Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674074 | 0.88 | CA9 (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL30701949 | 0.88 | CA9 (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL29068845 | 0.85 | HDAC4 (0.47) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL4579619 | 0.82 | HDAC4 (0.53) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL29788008 | 0.82 | HDAC4 (0.53) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL10536041 | 0.82 | HDAC4 (0.57) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL5804679 | 0.82 | HDAC4 (0.76) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL27490310 | 0.82 | HDAC4 (0.57) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL16812107 | 0.80 | HDAC4 (0.73) | HDAC4HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL28322511 | 0.80 | CYP1A1 (0.44) | HDAC4HDAC2HDAC8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304128-A | Method for continuously synthesizing biphenyl compound | 常州大学 | 2023-12-29 | — | — | CN | disclosed |
| US-20230192692-A1 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | TIANJIN NORMAL UNIVERSITY (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2022121977-A1 | PHARMACEUTICAL APPLICATION OF FUSED-RING PHENOLIC COMPOUND | 润佳（苏州）医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| US-11053188-B2 | Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides | SYNGENTA PARTICIPATIONS AG (CH) | 2021-07-06 | — | — | US | disclosed |
| WO-2021073456-A1 | MACROCYCLIC AND CAGE-LIKE MOLECULES BASED ON BIPHENYLARENE AND DERIVATIVE COMPOUNDS, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 天津师范大学 | 2021-04-22 | — | — | WO | disclosed |
| US-20200407311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-12-31 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110040091-A1 | PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040091-A1 | PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES | PCCA, GRHPR, GABRR2 | HDAC4 2806/4885HDAC2 1597/4885HDAC8 4013/4885 |
| US-20230192692-A1 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | TPMT, NUDT1, PNP | HDAC4 4177/4885HDAC2 2263/4885HDAC8 2534/4885 |
| US-20200407311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | TBCB, ADORA2B, ADRA2B | HDAC4 2297/4885HDAC2 808/4885HDAC8 1239/4885 |
| US-11053188-B2 | Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides | TBCB, ADORA2B, CCNB3 | HDAC4 2519/4885HDAC2 791/4885HDAC8 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.